225 related articles for article (PubMed ID: 10942240)
1. Calicheamicin-conjugated humanized anti-CD33 monoclonal antibody (gemtuzumab zogamicin, CMA-676) shows cytocidal effect on CD33-positive leukemia cell lines, but is inactive on P-glycoprotein-expressing sublines.
Naito K; Takeshita A; Shigeno K; Nakamura S; Fujisawa S; Shinjo K; Yoshida H; Ohnishi K; Mori M; Terakawa S; Ohno R
Leukemia; 2000 Aug; 14(8):1436-43. PubMed ID: 10942240
[TBL] [Abstract][Full Text] [Related]
2. Reduced effect of gemtuzumab ozogamicin (CMA-676) on P-glycoprotein and/or CD34-positive leukemia cells and its restoration by multidrug resistance modifiers.
Matsui H; Takeshita A; Naito K; Shinjo K; Shigeno K; Maekawa M; Yamakawa Y; Tanimoto M; Kobayashi M; Ohnishi K; Ohno R
Leukemia; 2002 May; 16(5):813-9. PubMed ID: 11986941
[TBL] [Abstract][Full Text] [Related]
3. Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia.
Hamann PR; Hinman LM; Hollander I; Beyer CF; Lindh D; Holcomb R; Hallett W; Tsou HR; Upeslacis J; Shochat D; Mountain A; Flowers DA; Bernstein I
Bioconjug Chem; 2002; 13(1):47-58. PubMed ID: 11792178
[TBL] [Abstract][Full Text] [Related]
4. [Cytocidal effects of gemtuzumab ozogamicin (CMA-676) on CD33-expressing acute myeloid leukemia cells, analysis P-glycoprotein and CD34 expression].
Matsui H; Takeshita A; Naito K; Onishi K; Ono R
Rinsho Ketsueki; 2002 May; 43(5):309-15. PubMed ID: 12096475
[No Abstract] [Full Text] [Related]
5. In vitro experimental (211)At-anti-CD33 antibody therapy of leukaemia cells overcomes cellular resistance seen in vivo against gemtuzumab ozogamicin.
Petrich T; Korkmaz Z; Krull D; Frömke C; Meyer GJ; Knapp WH
Eur J Nucl Med Mol Imaging; 2010 May; 37(5):851-61. PubMed ID: 20107790
[TBL] [Abstract][Full Text] [Related]
6. Gemtuzumab Ozogamicin (CMA-676, Mylotarg) for the treatment of CD33+ acute myeloid leukemia.
Voutsadakis IA
Anticancer Drugs; 2002 Aug; 13(7):685-92. PubMed ID: 12187324
[TBL] [Abstract][Full Text] [Related]
7. [Antibody directed therapy for leukemia].
Takeshita A; Naito K; Ohno R
Nihon Rinsho; 2002 Mar; 60(3):517-24. PubMed ID: 11904967
[TBL] [Abstract][Full Text] [Related]
8. Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate.
Sievers EL; Appelbaum FR; Spielberger RT; Forman SJ; Flowers D; Smith FO; Shannon-Dorcy K; Berger MS; Bernstein ID
Blood; 1999 Jun; 93(11):3678-84. PubMed ID: 10339474
[TBL] [Abstract][Full Text] [Related]
9. Multidrug resistance protein attenuates gemtuzumab ozogamicin-induced cytotoxicity in acute myeloid leukemia cells.
Walter RB; Raden BW; Hong TC; Flowers DA; Bernstein ID; Linenberger ML
Blood; 2003 Aug; 102(4):1466-73. PubMed ID: 12689934
[TBL] [Abstract][Full Text] [Related]
10. CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy.
Walter RB; Gooley TA; van der Velden VH; Loken MR; van Dongen JJ; Flowers DA; Bernstein ID; Appelbaum FR
Blood; 2007 May; 109(10):4168-70. PubMed ID: 17227830
[TBL] [Abstract][Full Text] [Related]
11. P-gp activity is a critical resistance factor against AVE9633 and DM4 cytotoxicity in leukaemia cell lines, but not a major mechanism of chemoresistance in cells from acute myeloid leukaemia patients.
Tang R; Cohen S; Perrot JY; Faussat AM; Zuany-Amorim C; Marjanovic Z; Morjani H; Fava F; Corre E; Legrand O; Marie JP
BMC Cancer; 2009 Jun; 9():199. PubMed ID: 19549303
[TBL] [Abstract][Full Text] [Related]
12. An anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Choice of linker.
Hamann PR; Hinman LM; Beyer CF; Lindh D; Upeslacis J; Flowers DA; Bernstein I
Bioconjug Chem; 2002; 13(1):40-6. PubMed ID: 11792177
[TBL] [Abstract][Full Text] [Related]
13. CMC-544 (inotuzumab ozogamicin) shows less effect on multidrug resistant cells: analyses in cell lines and cells from patients with B-cell chronic lymphocytic leukaemia and lymphoma.
Takeshita A; Shinjo K; Yamakage N; Ono T; Hirano I; Matsui H; Shigeno K; Nakamura S; Tobita T; Maekawa M; Ohnishi K; Sugimoto Y; Kiyoi H; Naoe T; Ohno R
Br J Haematol; 2009 Jun; 146(1):34-43. PubMed ID: 19388933
[TBL] [Abstract][Full Text] [Related]
14. Cytotoxic activity of gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukemia correlates with the expression of protein kinase Syk.
Balaian L; Ball ED
Leukemia; 2006 Dec; 20(12):2093-101. PubMed ID: 17051243
[TBL] [Abstract][Full Text] [Related]
15. Monoclonal antibodies to the myeloid stem cells: therapeutic implications of CMA-676, a humanized anti-CD33 antibody calicheamicin conjugate.
Bernstein ID
Leukemia; 2000 Mar; 14(3):474-5. PubMed ID: 10720144
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of gemtuzumab ozogamicin, an antibody-targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse.
Dowell JA; Korth-Bradley J; Liu H; King SP; Berger MS
J Clin Pharmacol; 2001 Nov; 41(11):1206-14. PubMed ID: 11697753
[TBL] [Abstract][Full Text] [Related]
17. Humanized M195 monoclonal antibody conjugated to recombinant gelonin: an anti-CD33 immunotoxin with antileukemic activity.
Pagliaro LC; Liu B; Munker R; Andreeff M; Freireich EJ; Scheinberg DA; Rosenblum MG
Clin Cancer Res; 1998 Aug; 4(8):1971-6. PubMed ID: 9717827
[TBL] [Abstract][Full Text] [Related]
18. What happened to anti-CD33 therapy for acute myeloid leukemia?
Jurcic JG
Curr Hematol Malig Rep; 2012 Mar; 7(1):65-73. PubMed ID: 22109628
[TBL] [Abstract][Full Text] [Related]
19. Multidrug transporter proteins and cellular factors involved in free and mAb linked calicheamicin-gamma1 (gentuzumab ozogamicin, GO) resistance and in the selection of GO resistant variants of the HL60 AML cell line.
Cianfriglia M; Mallano A; Ascione A; Dupuis ML
Int J Oncol; 2010 Jun; 36(6):1513-20. PubMed ID: 20428776
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and tolerability of gemtuzumab ozogamicin (anti-CD33 monoclonal antibody, CMA-676, Mylotarg) in children with relapsed/refractory myeloid leukemia.
Brethon B; Auvrignon A; Galambrun C; Yakouben K; Leblanc T; Bertrand Y; Leverger G; Baruchel A
BMC Cancer; 2006 Jun; 6():172. PubMed ID: 16805911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
